Phospho-BCL2 (S87) Antibody

What is the significance of BCL-2 phosphorylation at the S87 site?

Phosphorylation of BCL-2 at serine 87 (S87) represents a critical post-translational modification within the flexible loop domain (FLD) that bridges the BCL-2 homology motifs BH3 and BH4. This modification induces significant conformational changes in the protein structure. According to molecular dynamics simulation and NMR studies, S87 phosphorylation causes the peptide to adopt a curved conformation, with the phosphate group facing outward, making the SerPro motif more accessible to binding partners such as Pin1 . This structural rearrangement has profound implications for BCL-2's anti-apoptotic function and its interactions with other regulatory proteins in cell death pathways.

Which kinases are primarily responsible for phosphorylating BCL-2 at S87?

Research has consistently demonstrated that S87 in the flexible loop of BCL-2 serves as the primary phosphorylation site for two major kinases:

Both kinases show substrate specificity with the four known phosphorylation sites, with S87 being the preferred target . The flanking sequence of S87 appears to be conserved and consistent with the consensus sequence for ERK2 phosphorylation sites, which is PXaan(S/T)P, where Xaa is a neutral or basic amino acid and n = 1 or 2 residues .

What are the recommended protocols for detecting phosphorylated BCL-2 at S87 using antibody-based methods?

For optimal detection of phosphorylated BCL-2 at S87, researchers should consider the following methodological approach:

Western Blotting Protocol:

• Use fresh cell lysates treated with phosphatase inhibitors

• Recommended antibody dilutions: 1:500-1:2000

• Validation controls: Include phospho-peptide blocking controls to confirm specificity

• Positive controls: Nocodazole-treated HeLa cells (1μg/ml for 18h) show strong S87 phosphorylation

• Sample preparation: Cells should be lysed in buffer containing 50mM Tris-HCl (pH 7.4), 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and protease/phosphatase inhibitor cocktail

Immunohistochemistry Protocol:

• Recommended antibody dilutions: 1:100-1:300

• Antigen retrieval: Citrate buffer (pH 6.0) heating for 20 minutes

• Validation: Include phospho-peptide blocking controls to confirm specificity

• Detection systems: Use polymer-based detection systems for enhanced sensitivity

Researchers should note that the SP66 antibody clone has shown higher detection rates (80%) compared to other antibody clones like 124 (34%) and E17 (62%) in some comparative studies of BCL-2 detection, though these studies were not specifically examining phospho-S87 .

How can mutagenesis approaches be used to study the functional consequences of S87 phosphorylation?

Site-directed mutagenesis offers powerful insights into S87 phosphorylation effects by creating phosphomimetic or phospho-deficient mutants:

Recommended mutation strategies:

• Phosphomimetic mutations: S87E (serine to glutamic acid) substitution mimics constitutive phosphorylation by introducing negative charge

• Phospho-deficient mutations: S87A (serine to alanine) prevents phosphorylation at this site

• Compound mutations: Create multiple mutations (e.g., T69E/S70E/S87E or "EEE") to study effects of multi-site phosphorylation

Key experimental findings using these approaches:

• S87E single mutations and EEE triple mutations both produce altered mobility patterns of BCL-2 in denaturing gel electrophoresis, suggesting that S87 phosphorylation induces conformational changes detectable even under denaturing conditions

• Compound mutants like T69A/S70A/S87E (AAE) can help isolate the specific contribution of S87 phosphorylation in the context of other potential phosphorylation sites

• Stably transfected cell lines expressing these mutants provide models for studying long-term functional consequences

How does phosphorylation at S87 alter BCL-2's interaction with binding partners in the apoptotic machinery?

Phosphorylation at S87 creates a binding interface that facilitates interaction with specific regulatory proteins:

Pin1 binding interaction:

• Phosphorylated S87 creates a pSer-Pro motif recognized by the WW domain of Pin1

• Molecular dynamics simulations reveal 6-7 hydrogen bonds formed between pS87 peptide and Pin1's WW domain

• R17 in Pin1 forms 3-4 hydrogen bonds with phosphoserine, serving as the major contributor to binding

• The interaction is stabilized by both hydrophilic interactions with the phosphate group and hydrophobic interactions between proline in the pSer-Pro motif and conserved residues Y23 and W34 in Pin1

This interaction with Pin1, a peptidyl-prolyl isomerase, may induce further conformational changes in BCL-2, potentially affecting its interactions with pro-apoptotic proteins such as BAX and BAK. The conformational change observed by CD spectroscopy shows a notable reduction in random coil content in phosphorylated BCL-2 , suggesting a more structured conformation that may alter binding affinities for various partners.

What is the interplay between phosphorylation at S87 and other post-translational modifications of BCL-2?

BCL-2 undergoes multiple post-translational modifications that interact in complex ways:

Cross-talk between phosphorylation sites:

• Phosphorylation at S87 may influence the accessibility of other sites (T69, S70, T74) to kinases and phosphatases

• Multi-site phosphorylation (T69/S70/S87) appears to have distinct effects compared to single-site phosphorylation

Interaction with ubiquitination pathways:

• BCL-2 can be ubiquitinated by multiple E3 ligases including SCF(FBXO10) and XIAP, leading to proteasomal degradation

• Phosphorylation may regulate accessibility of ubiquitination sites or interaction with E3 ligases

• Monoubiquitination by PRKN increases BCL-2 stability, which may be influenced by phosphorylation status

Proteolytic cleavage:

• BCL-2 is cleaved by caspases during apoptosis, removing the BH4 motif and converting it to a pro-apoptotic form

• Phosphorylation at S87 may alter the accessibility of cleavage sites or interaction with caspases

How should experiments be designed to investigate the role of S87 phosphorylation in response to specific stimuli?

When studying stimulus-specific S87 phosphorylation, researchers should implement the following experimental design principles:

Kinetics of phosphorylation:

• Perform time-course experiments (5min, 15min, 30min, 1h, 2h, 4h, 8h, 24h)

• Include appropriate positive controls (e.g., microtubule-targeting drugs like paclitaxel and colchicine known to induce BCL-2 phosphorylation)

• Monitor multiple phosphorylation sites simultaneously using site-specific antibodies

Kinase inhibitor strategy:

Phosphatase analysis:

• Include phosphatase inhibitors (e.g., okadaic acid at 100nM for PP2A inhibition)

• Consider in vitro dephosphorylation assays with purified phosphatases (PP1, PP2A, PP2B/calcineurin)

• Monitor dephosphorylation kinetics to understand the dynamic regulation of S87 phosphorylation

What cellular models are most appropriate for studying the functional consequences of BCL-2 S87 phosphorylation?

Selection of appropriate cellular models is critical for understanding context-specific functions of S87 phosphorylation:

Recommended cell models:

• Hematopoietic cell lines: IL-3-dependent NSF/N1.H7 cells have been successfully used to study BCL-2 phosphorylation

• Cancer cell lines: Lung cancer H157 cells express BCL-2 and respond to phosphorylation-inducing stimuli

• Neuronal models: BCL-2 plays important roles in neuronal survival, making neuronal cell lines or primary neurons valuable models

• Cell lines with minimal endogenous BCL-2: Allow clean interpretation of transfected mutant effects

Experimental approaches:

• Create stable cell lines expressing WT, S87A, or S87E BCL-2 with quantitatively similar expression levels

• Use inducible expression systems to control timing and level of expression

• Employ CRISPR/Cas9 to introduce phospho-mimetic or phospho-deficient mutations at the endogenous locus

• Consider 3D culture models or organoids for more physiologically relevant contexts

How do we reconcile contradictory findings regarding the effect of S87 phosphorylation on BCL-2's anti-apoptotic function?

The literature presents seemingly contradictory findings regarding S87 phosphorylation effects on BCL-2 function:

Supporting enhanced anti-apoptotic function:

• Several in vivo studies report that BCL-2 phosphorylated at sites T69, S70, and S87 (or with phosphomimetic mutations like T69E/S70E/S87E) shows enhanced protection against apoptotic cell death

• Studies using the S87E phosphomimetic mutation demonstrate increased protection against paclitaxel-induced apoptosis

Supporting decreased anti-apoptotic function:

• Some studies suggest phosphorylation represents inactivation of BCL-2 during cell cycle progression as a normal physiologic process at G2/M

• JNK-mediated phosphorylation has been linked to BCL-2 inactivation under certain stress conditions

Reconciliation approaches:

• Context-dependency: The effect may depend on cell type, stimulus, and which sites are co-phosphorylated

• Temporal dynamics: Short-term vs. long-term effects may differ

• Interaction partners: Available binding partners may determine functional outcome

• Methodology differences: Different detection methods or experimental conditions

• Threshold effects: The degree of phosphorylation may determine functional outcomes

What are the most reliable methodological approaches to resolve conflicting data on S87 phosphorylation?

To address contradictions in the field, researchers should implement rigorous methodological approaches:

Direct comparison studies:

• Use the same cell systems and experimental conditions to test competing hypotheses

• Employ multiple complementary techniques to assess apoptosis (e.g., Annexin V/PI staining, caspase activity assays, cytochrome c release, PARP cleavage)

• Measure both phosphorylation and functional outcomes simultaneously in the same samples

Enhanced controls and validation:

• Include both phospho-mimetic (S87E) and phospho-deficient (S87A) mutants

• Verify antibody specificity using phospho-peptide blocking controls

• Use multiple antibody clones targeting different epitopes to confirm findings

• Confirm phosphorylation by mass spectrometry when possible

Systems biology approaches:

• Consider the entire BCL-2 interactome rather than isolated interactions

• Use computational modeling to predict effects of S87 phosphorylation in different contexts

• Integrate proteomics, interactomics, and functional data to build comprehensive models

What emerging technologies could advance our understanding of S87 phosphorylation dynamics in living cells?

Several cutting-edge technologies hold promise for illuminating S87 phosphorylation dynamics:

Live-cell phosphorylation sensors:

• Develop FRET-based biosensors that report BCL-2 S87 phosphorylation status in real-time

• Create split fluorescent protein systems where reconstitution depends on S87 phosphorylation

• Employ phospho-specific nanobodies fused to fluorescent proteins for live imaging

Advanced microscopy approaches:

• Super-resolution microscopy to visualize subcellular localization of phosphorylated BCL-2

• Single-molecule tracking to monitor dynamics of individual BCL-2 molecules after phosphorylation

• FLIM-FRET (Fluorescence Lifetime Imaging Microscopy with FRET) for quantitative analysis of conformational changes

Mass spectrometry innovations:

• Targeted MS approaches for absolute quantification of phosphorylated vs. non-phosphorylated forms

• Cross-linking MS to map interaction interfaces that change upon phosphorylation

• Top-down proteomics to analyze intact BCL-2 with all its modifications simultaneously

How might understanding S87 phosphorylation contribute to therapeutic strategies targeting BCL-2 in disease?

Insights into S87 phosphorylation offer several therapeutic avenues:

Drug design strategies:

• Develop small molecules that specifically bind to phosphorylated S87 to modulate BCL-2 function

• Create peptide mimetics that compete with natural binding partners of phosphorylated BCL-2

• Design kinase inhibitors with specificity for BCL-2 S87 phosphorylation

Combination therapy approaches:

• Pair BCL-2 inhibitors (e.g., venetoclax) with drugs that modulate S87 phosphorylation

• Target both BCL-2 and its phosphorylation-dependent binding partners like Pin1

• Consider cell cycle-specific timing of treatment based on phosphorylation patterns

Biomarker development:

• Use phospho-S87 detection as a predictive biomarker for response to BCL-2-targeted therapies

• Develop diagnostic assays based on S87 phosphorylation status to guide treatment decisions

• Monitor changes in S87 phosphorylation as a pharmacodynamic marker during treatment

These research directions could ultimately lead to more precise targeting of BCL-2 in diseases like cancer, where its anti-apoptotic function contributes to treatment resistance and disease progression.